FRM
INDV icon

Fox Run Management’s Indivior Pharmaceuticals INDV Stock Holding History

Fox Run Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
24,876
+11,761
+90% +$427K 0.17% 176
2026
Q1 		$377K Buy
+13,115
New +$433K 0.07% 556

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's INDV Position: Q2 2026 in Review

Fox Run Management increased its Indivior Pharmaceuticals (INDV) stake by 90% in Q2 2026, buying an estimated $427K and bringing the position to 24,876 shares worth $1.02M. The position accounts for 0.17% of the portfolio, ranked #176.

Fox Run Management first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Fox Run Management held 24,876 shares of Indivior Pharmaceuticals worth $1.02M as of Q2 2026.
  • Fox Run Management bought 11,761 Indivior Pharmaceuticals shares in Q2 2026, an estimated $427K.
  • Indivior Pharmaceuticals made up 0.17% of Fox Run Management's portfolio in Q2 2026, its #176 holding.
  • Fox Run Management first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.